A phase 3 randomized trial of 18,476 adults found that Pfizer’s quadrivalent nucleoside-modified mRNA (modRNA) influenza vaccine demonstrated statistically superior efficacy compared with a licensed quadrivalent inactivated vaccine during the…
Pfizer’s mRNA Influenza Vaccine Shows Superior Efficacy to Inactivated Vaccine in Phase 3 Trial
